Skip to main content

Table 1 Clinical characteristics of the 51 children who underwent haploidentical hematopoietic stem cell transplantation

From: Cyclosporine A-related neurotoxicity after haploidentical hematopoietic stem cell transplantation in children with hematopathy

Characteristic Value
Age at HID-HSCT (years), median (range) 8 (1.1–18)
Gender, n (%)
 Female 12 (23.5%)
 Male 39 (76.5%)
Primary disease, n (%)
 Acute lymphoblastic leukemia 14 (27.4%)
 Acute myeloid leukemia 25 (49.0%)
 Myelodysplastic syndrome-secondary acute myeloid leukemia 4 (7.9%)
 Advanced myelodysplastic syndrome 2 (3.9%)
 Acquired severe aplastic anemia 6 (11.8%)
aRemission status, n (%)
 First complete remission (CR1) 24 (55.8%)
 Second complete remission (CR2) 5 (11.6%)
 Not in remission 14 (32.6%)
Relationship of donor to recipient, n (%)
 Parent 49 (96.1%)
 Sibling 2 (3.9%)
ABO blood type match between donor and recipient, n (%)
 Matched 30 (58.8%)
 Mismatched 21 (41.2%)
Donor-recipient gender, n (%)
 Male-male 18 (35.3%)
 Male-female 9 (17.6%)
 Female-female 3 (5.9%)
 Female-male 21 (41.2%)
Time to engraftment (days), median (range)
 Neutrophils 12 (10–22)
 Thrombocytes 13 (7–35)
Number of CD34+ cells infused (× 106/kg), median (range) 5.33 (2.3–28)
Follow-up time (days), median (range) 405 (44–1432)
  1. aRemission status is for 43 children with acute leukemia. HID-HSCT, haploidentical hematopoietic stem cell transplantation